COVID-19 related outcomes among individuals with neurodegenerative diseases: a cohort analysis in the UK biobank

BMC Neurology

Unnur Valdimarsdottir¹  Wenwen Chen²  Fang Fang³  Maria Feychting³  Yuanyuan Qu⁴  Yao Hu⁴  Yajing Sun⁴  Huazhen Yang⁴  Can Hou⁴  Zhiye Ying⁴  Hanyue Zhang⁴  Huan Song⁵  Yihan Hu⁶ 

[1] Center of Public Health Sciences, Faculty of Medicine, University of Iceland, 101, Reykjavík, Iceland;Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, 171 77, Stockholm, Sweden;Division of Nephrology, Kidney Research Institute, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, 610041, Chengdu, China;Institute of Environmental Medicine, Karolinska Institutet, 171 77, Stockholm, Sweden;West China Biomedical Big Data Center and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Guo Xue Lane 37, 610041, Chengdu, China;Medical Big Data Center, Sichuan University, 610041, Chengdu, China;West China Biomedical Big Data Center and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Guo Xue Lane 37, 610041, Chengdu, China;Medical Big Data Center, Sichuan University, 610041, Chengdu, China;Center of Public Health Sciences, Faculty of Medicine, University of Iceland, 101, Reykjavík, Iceland;West China Biomedical Big Data Center and National Clinical Research Center for Geriatrics, West China Hospital, Sichuan University, Guo Xue Lane 37, 610041, Chengdu, China;Medical Big Data Center, Sichuan University, 610041, Chengdu, China;Institute of Environmental Medicine, Karolinska Institutet, 171 77, Stockholm, Sweden;

关键词: Neurodegenerative diseases;    COVID-19;    Cohort study;    UK biobank;   

DOI  :  10.1186/s12883-021-02536-7

来源: Springer

【 摘 要 】

BackgroundAn increased susceptibility to COVID-19 has been suggested for individuals with neurodegenerative diseases, but data are scarce from longitudinal studies.MethodsIn this community-based cohort study, we included 96,275 participants of the UK Biobank who had available SARS-CoV-2 test results in Public Health England. Of these, 2617 had a clinical diagnosis of neurodegenerative diseases in the UK Biobank inpatient hospital data before the outbreak of COVID-19 (defined as January 31st, 2020), while the remaining participants constituted the reference group. We then followed both groups from January 31st, 2020 to June 14th, 2021 for ascertainment of COVID-19 outcomes, including any COVID-19, inpatient care for COVID-19, and COVID-19 related death. Logistic regression was applied to estimate the association between neurogenerative disease and risks of COVID-19 outcomes, adjusted for multiple confounders and somatic comorbidities.ResultsWe observed an elevated risk of COVID-19 outcomes among individuals with a neurodegenerative disease compared with the reference group, corresponding to a fully adjusted odds ratio of 2.47 (95%CI 2.25–2.71) for any COVID-19, 2.18 (95%CI 1.94–2.45) for inpatient COVID-19, and 3.67 (95%CI 3.11–4.34) for COVID-19 related death. Among individuals with a positive test result for SARS-CoV-2, individuals with neurodegenerative diseases had also a higher risk of COVID-19 related death than others (fully adjusted odds ratio 2.08; 95%CI 1.71–2.53).ConclusionAmong UK Biobank participants who received at least one test for SARS-CoV-2, a pre-existing diagnosis of neurodegenerative disease was associated with a subsequently increased risk of COVID-19, especially COVID-19 related death.

【 授权许可】

CC BY